Ngm Biopharmaceuticals, Inc.

Betty Chan Li

Wenyan Shen

Taruna Arora

Hugo Matern

Yu Chen

Kalyani Mondal

Yan Wang

Suzanne Christine Crawley

Daniel David Kaplan

Jer-Yuan Hsu

Julie Michelle Roda

Kevin James Paavola

Seth Malmersjö

Vicky Yi-Bing Lin

James Robert Sissons

Jonathan Sitrin

Xuan Zhao

Bin Fan

Lee Benjamin Rivera

The present disclosure provides binding proteins, such as antibodies or binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use such as in producing an antibody or binding fragment thereof. The present disclosure also provides vectors and cells comprising polynucleotides encoding antibodies or binding fragments thereof that bind beta klotho, including human beta klotho.

Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof

The present disclosure provides binding agents, such as antibodies, that specifically bind LAIR-1, including human LAIR-1, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

LAIR-1-binding agents and methods of use thereof

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

ILT3-binding agents and methods of use thereof

The present disclosure provides binding proteins, such as antibodies, and binding fragments thereof, that bind beta klotho, including human beta klotho, and exemplary specific sequences of their complementarity determining regions, variable regions, heavy chains, and light chains. The present disclosure also provides method of making the antibody or fragment thereof and methods of their use, including, in activating beta-klotho/FGF receptor complex, inducing FGF19-like and/or FGF21-like signaling, improving glucose and lipid metabolism, and treatment of nonalcoholic steatohepatitis.

Anti-human beta klotho antibody or binding fragment thereof and methods of their use

The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis. The present disclosure also provides exemplary specific sequences of complementarity determining regions, variable regions, heavy chains, and light chains of the antibodies and/or binding fragments thereof.

Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof

The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Beta klotho-binding proteins

Beta klotho-binding proteins and methods of use thereof

Beta-klotho binding proteins

Beta klotho binding proteins and methods of use thereof

Growing community of inventors

Millbrae, CA, United States of America

Betty Chan Li